Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development
- PMID: 38149013
- PMCID: PMC10750358
- DOI: 10.3389/fcimb.2023.1297281
Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development
Abstract
Background: New drugs targeting antimicrobial resistant pathogens, including Pseudomonas aeruginosa, have been challenging to evaluate in clinical trials, particularly for the non-ventilated hospital-acquired pneumonia and ventilator-associated pneumonia indications. Development of new antibacterial drugs is facilitated by preclinical animal models that could predict clinical efficacy in patients with these infections.
Methods: We report here an FDA-funded study to develop a rabbit model of non-ventilated pneumonia with Pseudomonas aeruginosa by determining the extent to which the natural history of animal disease reproduced human pathophysiology and conducting validation studies to evaluate whether humanized dosing regimens of two antibiotics, meropenem and tobramycin, can halt or reverse disease progression.
Results: In a rabbit model of non-ventilated pneumonia, endobronchial challenge with live P. aeruginosa strain 6206, but not with UV-killed Pa6206, caused acute respiratory distress syndrome, as evidenced by acute lung inflammation, pulmonary edema, hemorrhage, severe hypoxemia, hyperlactatemia, neutropenia, thrombocytopenia, and hypoglycemia, which preceded respiratory failure and death. Pa6206 increased >100-fold in the lungs and then disseminated from there to infect distal organs, including spleen and kidneys. At 5 h post-infection, 67% of Pa6206-challenged rabbits had PaO2 <60 mmHg, corresponding to a clinical cut-off when oxygen therapy would be required. When administered at 5 h post-infection, humanized dosing regimens of tobramycin and meropenem reduced mortality to 17-33%, compared to 100% for saline-treated rabbits (P<0.001 by log-rank tests). For meropenem which exhibits time-dependent bactericidal activity, rabbits treated with a humanized meropenem dosing regimen of 80 mg/kg q2h for 24 h achieved 100% T>MIC, resulting in 75% microbiological clearance rate of Pa6206 from the lungs. For tobramycin which exhibits concentration-dependent killing, rabbits treated with a humanized tobramycin dosing regimen of 8 mg/kg q8h for 24 h achieved Cmax/MIC of 9.8 ± 1.4 at 60 min post-dose, resulting in 50% lung microbiological clearance rate. In contrast, rabbits treated with a single tobramycin dose of 2.5 mg/kg had Cmax/MIC of 7.8 ± 0.8 and 8% (1/12) microbiological clearance rate, indicating that this rabbit model can detect dose-response effects.
Conclusion: The rabbit model may be used to help predict clinical efficacy of new antibacterial drugs for the treatment of non-ventilated P. aeruginosa pneumonia.
Keywords: Pseudomonas aeruginosa; meropenem; non-ventilated pneumonia model; preclinical efficacy model validation; rabbit model; tobramycin.
Copyright © 2023 Gras, Vu, Nguyen, Tran, Mao, Tran, Mai, Dong, Jung, Iorio, Povoa, Pinheiro, Aguiar-Alves, Weiss, Zheng, Cheng, Stover, Sellman, DiGiandomenico, Gibault, Valour and Diep.
Conflict of interest statement
Authors BZ, LC, CS, AD and BS are or were employed by AstraZeneca. Author BD previously received funding from AstraZeneca, Pfizer, Merck, Arsanis, ContraFect, and Integrated Biotherapeutics for preclinical studies using earlier iterations of the rabbit model of non-ventilated pneumonia. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0272420. doi: 10.1128/AAC.02724-20. Epub 2021 Jun 17. Antimicrob Agents Chemother. 2021. PMID: 33972247 Free PMC article.
-
Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model.J Antimicrob Chemother. 2025 Jun 3;80(6):1552-1559. doi: 10.1093/jac/dkaf100. J Antimicrob Chemother. 2025. PMID: 40152266 Free PMC article.
-
Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa.mBio. 2024 Feb 14;15(2):e0316523. doi: 10.1128/mbio.03165-23. Epub 2024 Jan 18. mBio. 2024. PMID: 38236031 Free PMC article.
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
-
Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin.Diagn Microbiol Infect Dis. 2003 Oct;47(2):427-30. doi: 10.1016/s0732-8893(03)00135-4. Diagn Microbiol Infect Dis. 2003. PMID: 14522517 Review.
Cited by
-
Animal models of Klebsiella pneumoniae mucosal infections.Front Microbiol. 2024 Mar 15;15:1367422. doi: 10.3389/fmicb.2024.1367422. eCollection 2024. Front Microbiol. 2024. PMID: 38559342 Free PMC article. Review.
-
Vascular endothelial cell injury: causes, molecular mechanisms, and treatments.MedComm (2020). 2025 Jan 16;6(2):e70057. doi: 10.1002/mco2.70057. eCollection 2025 Feb. MedComm (2020). 2025. PMID: 39931738 Free PMC article. Review.
-
Development of a bivalent protein subunit vaccine against infection by Pseudomonas aeruginosa and Staphylococcus aureus.NPJ Vaccines. 2025 Jul 25;10(1):169. doi: 10.1038/s41541-025-01220-y. NPJ Vaccines. 2025. PMID: 40715169 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical